Synopsis
Explain how UK population cancer screening differs from diagnosis, identify current programme pathways, support informed choice, and respond safely to abnormal, incomplete or symptom-discordant results.
- Screening offers a test to an apparently well defined population to reduce disease-specific harm; it is not a guarantee that cancer is absent.
- UK population programmes include bowel, breast and cervical screening. In England, targeted lung cancer screening is rolling out for people aged 55–74 with a smoking history: risk assessment determines who is offered low-dose CT, and current availability and criteria must be checked locally and by UK nation.
- The first-line test is programme-specific: for example faecal immunochemical testing in bowel screening and primary HPV testing in cervical screening pathways.
- An abnormal screen requires the programme's diagnostic assessment; it is not itself a cancer diagnosis and many recalled people will not have malignancy.
- Symptoms use a symptomatic pathway regardless of age or recent screening result, because screening sensitivity is incomplete and interval cancers occur.
- Informed choice includes benefits, false positives, false negatives, overdiagnosis, anxiety and procedural harm, presented accessibly without coercion.
- Non-response can reflect language, disability, trauma, deprivation or access barriers; services should offer reasonable adjustment rather than labelling disengagement.
- Incidental or private tests outside an evaluated programme may create uncertain findings and should not be treated as equivalent to national screening.
Key red flags
New bleeding, lump, unexplained weight loss or persistent change requires diagnostic assessment even after a recent negative screen.
Investigation priorities
Confirm whether the person belongs to the current invited cohort.
Management branches
An eligible person receives or has missed a screening invitation.
- Explain the programme's purpose, likely next steps, main benefits and harms in the person's preferred accessible format.
- Check practical barriers and arrange translated material, accessible venue, bowel-test support or other reasonable adjustment through the programme.
- Respect an informed decision to accept or decline, while documenting how to seek advice if symptoms develop.
Possible-cancer symptoms appear before, during or after routine screening.
- Assess acuity, examination and the appropriate NG12 symptom criteria without repeating a screening test as a diagnostic substitute.
- Refer to the site-specific diagnostic pathway or emergency service and provide safety-net timing for progression or non-resolution.
- Tell the screening programme when relevant, but do not wait for its next invitation or routine recall decision.